| __timestamp | Ionis Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 72471000 |
| Thursday, January 1, 2015 | 37173000 | 89204000 |
| Friday, January 1, 2016 | 48616000 | 106010000 |
| Sunday, January 1, 2017 | 108488000 | 137905000 |
| Monday, January 1, 2018 | 244622000 | 159888000 |
| Tuesday, January 1, 2019 | 287000000 | 158425000 |
| Wednesday, January 1, 2020 | 354000000 | 200677000 |
| Friday, January 1, 2021 | 186000000 | 304759000 |
| Saturday, January 1, 2022 | 151000000 | 377221000 |
| Sunday, January 1, 2023 | 232600000 | 336361000 |
| Monday, January 1, 2024 | 267474000 |
Unlocking the unknown
In the competitive landscape of biopharmaceuticals, understanding spending patterns is crucial. From 2014 to 2023, Ionis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Ionis Pharmaceuticals saw a dramatic increase, peaking in 2020 with a 1,660% rise from 2014 levels. However, by 2023, their expenses had decreased by 34% from the 2020 peak. In contrast, Supernus Pharmaceuticals exhibited a steady upward trend, with a notable 364% increase over the same period, reaching their highest SG&A spending in 2022. This divergence highlights differing strategic priorities and market responses. As the industry evolves, these spending patterns offer insights into each company's operational focus and market positioning.
Comparing SG&A Expenses: AstraZeneca PLC vs Ionis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Who Optimizes SG&A Costs Better? Axsome Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Supernus Pharmaceuticals, Inc.